Bernard Cambou, PhD. MBA is a strategic advisor to the biopharmaceutical industry, and he is owner and managing partner of US-based Arverne Bio specialized in transactional and operational endeavors on behalf of clients in the US, Europe and China.
In addition to his consulting roles, Dr. Cambou is President of PriZm Therapeutics, which is currently in Phase 3 for the treatment of a rare pediatric disease.
Prior to founding Arverne Bio, Dr. Cambou was a biotechnology executive with broad international experience in Europe, US and Japan, in Research and Development, Business Development, Venture Capital and Venture Capital-backed company and / or CEO positions.
Dr. Cambou holds an engineering degree in agronomy/microbiology. He is a post-graduate from the Pasteur Institute (Masters of Science degree), and the University of Technology of Compiègne (Masters of Science and Doctoral degrees). In the early 80s, he spent two and a half years at the Massachusetts Institute of Technology, Cambridge, MA as a post-doctoral fellow. He holds an Executive MBA degree from ESSEC, Paris.